Indications for: Phendimetrazine Tartrate Ext-Rel

Management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of ≥30kg/m2 or ≥27kg/m2 in the presence of other risk factors (eg, controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.

Adult Dosage:

≥17yrs: 1 cap in the AM (30–60mins before morning meal).

Children Dosage:

<17yrs: not recommended.

Phendimetrazine Tartrate Ext-Rel Contraindications:

History of cardiovascular disease (eg, coronary artery disease, stroke, arrhythmias, CHF, uncontrolled hypertension, pulmonary hypertension). Hyperthyroidism. Glaucoma. Agitated states. History of drug abuse. Pregnancy. Nursing mothers. Concomitant other CNS stimulants, anorectic agents. During or within 14 days of MAOIs.

Phendimetrazine Tartrate Ext-Rel Warnings/Precautions:

Increased risk of pulmonary hypertension with repeated courses. Heart murmer, valvular heart disease: not recommended. Do not exceed max recommended dose. Obtain baseline cardiac evaluation prior to initiating therapy to detect pre-existing valvular heart disease or pulmonary hypertension. Mild hypertension. Diabetes. Prescribe minimal supply to avoid overdose. Renal impairment. Elderly.

Phendimetrazine Tartrate Ext-Rel Classification:

Phenylalkylamine sympathomimetic amine.

Phendimetrazine Tartrate Ext-Rel Interactions:

See Contraindications. Hypertensive crisis with MAOIs. Anorectic agents use within prior year: not recommended. Insulin and oral hyperglycemic requirements may be altered. May decrease hypotensive effect of guanethidine, adrenergic neuron blocking drugs. Concomitant alcohol may result in adverse drug reaction.

Adverse Reactions:

Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevated BP, ischemic events, overstimulation, restlessness, insomnia, agitation, flushing, tremor, sweating, dizziness, headache, psychotic state, blurred vision, dry mouth, GI upset, constipation, stomach pain, urinary frequency, dysuria, changes in libido; tolerance (discontinue when occurs), withdrawal effects (w. prolonged use).


Formerly known under the brand name Bontril.

Drug Elimination:

The major route of elimination is via the kidneys where most of the drug and metabolites are excreted. Some of the drug is metabolized to phenmetrazine and also phendimetrazine-N-oxide.

The average half-life of elimination is about 3.7 hours for both the extended-release and immediate release forms. 

How Supplied:

Caps—100, 1000